Published in BioDrugs on December 01, 2013
Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A (2016) 0.77
The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13. Oncotarget (2016) 0.77
NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. Nano Res (2016) 0.76
Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine. J Biomed Sci (2016) 0.75
Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain. Int J Mol Sci (2017) 0.75
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology (2014) 0.75
Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. Adv Funct Mater (2017) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol (1996) 9.77
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 8.11
Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 7.89
Fibronectin at a glance. J Cell Sci (2002) 5.51
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol (1985) 4.44
Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 4.27
Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl (2010) 4.14
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A (1991) 3.76
Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv (2004) 3.65
Barriers to drug delivery in solid tumors. Sci Am (1994) 3.57
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 3.24
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 2.85
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med (1998) 2.42
Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem (1993) 2.29
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol (2000) 2.18
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol (1992) 2.12
Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev (1989) 2.08
Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med (1990) 2.02
Aminopeptidases: structure and function. FASEB J (1993) 1.91
Human TNF mutants with selective activity on the p55 receptor. Nature (1993) 1.91
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood (1993) 1.77
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res (2002) 1.76
The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med (2008) 1.70
Therapeutic cancer targeting peptides. Biopolymers (2002) 1.70
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest (2002) 1.67
Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun (2006) 1.58
The neovasculature homing motif NGR: more than meets the eye. Blood (2008) 1.46
Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) (2009) 1.44
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood (2001) 1.41
Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem (2006) 1.39
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res (2006) 1.37
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 1.22
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 1.17
Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med (1992) 1.17
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol (2003) 1.16
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol (1991) 1.16
The structure and main functions of aminopeptidase N. Curr Med Chem (2007) 1.14
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer (2000) 1.14
Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res (2004) 1.12
Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol (1996) 1.12
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer (2010) 1.08
Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res (2005) 1.08
TumorHoPe: a database of tumor homing peptides. PLoS One (2012) 1.07
Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer (1996) 1.06
Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res (2008) 1.06
Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J (1992) 1.05
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem (2010) 1.05
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer (2000) 1.04
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. J Biol Chem (2008) 1.03
Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med (1994) 1.03
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol (2010) 1.03
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer (2009) 1.03
Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol (1994) 1.02
Tumor necrosis factor-alpha augments pulmonary arterial transendothelial albumin flux in vitro. Am J Physiol (1990) 1.00
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res (2010) 1.00
Isoaspartate-dependent molecular switches for integrin-ligand recognition. J Cell Sci (2011) 1.00
Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J (2004) 0.99
Antibody-cytokine fusion proteins. Arch Biochem Biophys (2012) 0.98
Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol (2011) 0.97
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res (2008) 0.97
Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res (2006) 0.96
cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol (2006) 0.96
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res (2003) 0.95
High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer (1995) 0.94
Design and chemical synthesis of integrin ligands. Methods Enzymol (2007) 0.94
High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a. Cytotherapy (2007) 0.93
Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res (2004) 0.93
Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. FASEB J (2007) 0.93
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. Mol Cancer Ther (2008) 0.92
Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm (2013) 0.91
Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy. Cancer Res (2011) 0.91
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res (1997) 0.90
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res (2011) 0.90
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther (2004) 0.89
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 0.89
Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res (1999) 0.88
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 0.88
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer (2010) 0.87
Tumour necrosis factor: strategies for improving the therapeutic index. J Drug Target (1998) 0.85
Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues. J Histochem Cytochem (2011) 0.84
Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res (2008) 0.84
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol (2003) 2.65
Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J (2007) 1.81
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
The neovasculature homing motif NGR: more than meets the eye. Blood (2008) 1.46
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res (2006) 1.37
Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem (2002) 1.22
Targeted drug delivery and penetration into solid tumors. Med Res Rev (2011) 1.19
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 1.17
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer (2010) 1.08
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. J Biol Chem (2008) 1.03
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol (2010) 1.03
Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol (2010) 1.02
Isoaspartate-dependent molecular switches for integrin-ligand recognition. J Cell Sci (2011) 1.00
Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J (2004) 0.99
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol (2008) 0.98
Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer (2004) 0.98
Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol (2011) 0.97
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol (2012) 0.97
A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood (2012) 0.96
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release (2010) 0.96
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer (2013) 0.95
Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res (2004) 0.93
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. Mol Cancer Ther (2008) 0.92
Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy. Cancer Res (2011) 0.91
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol (2009) 0.91
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res (2011) 0.90
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes (2012) 0.90
The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res (2012) 0.90
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol (2005) 0.90
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics (2012) 0.89
Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res (2002) 0.86
Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. Angew Chem Int Ed Engl (2013) 0.85
Mediastinal follicular dendritic cell sarcoma. Haematologica (2003) 0.85
Body mass index, cardiovascular risk factors, and carotid intima-media thickness in a pediatric population in southern Italy. J Pediatr Gastroenterol Nutr (2010) 0.85
Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. J Control Release (2013) 0.84
Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res (2008) 0.84
Intestinal glucose uptake protects liver from lipopolysaccharide and D-galactosamine, acetaminophen, and alpha-amanitin in mice. Am J Pathol (2009) 0.82
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? J Thorac Oncol (2008) 0.82
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus. BMC Infect Dis (2014) 0.81
Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer (2004) 0.81
Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. J Biol Chem (2002) 0.80
Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling. J Biol Chem (2013) 0.79
Endothelial growth factor receptor inhibition after radiotherapy. J Thorac Oncol (2007) 0.78
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer (2014) 0.77
Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci (2010) 0.77
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Med Oncol (2014) 0.77
Influence of the duration of intravenous drug administration on tumor uptake. Front Oncol (2013) 0.77
The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. Dig Dis Sci (2012) 0.76
Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. J Thorac Oncol (2010) 0.75
Rare HVR1-HCV genotype 1b variants in patients with B non Hodgkin's lymphoma. Comparison with viral sequences detected in cases of lymphoproliferative disorders and B cell compartmentalisation. New Microbiol (2007) 0.75
NGR-TNF engineering with an N-terminal serine reduces degradation and post-translational modifications and improves its tumor targeting activity. Mol Pharm (2020) 0.75